Dataset related to article "Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study "

This record contains raw data related to article “Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study" Abstract Scalp is a frequent localization of psoriasis that has a massive impact on patient's quality of life. Managing this psoriasis' manifestation is often challenging, thus biologic drugs are widely used as a treatment option in refractory scalp psoriasis. The aim of our study is to retrospectively compare the efficacy of anti-interleukin (IL) 23 drugs (guselkumab, tildrakizumab, risankizumab) and anti-IL17 or anti-IL17RA biologics (secukinumab, ixekizumab, and brodalumab) in real-life patients affected by scalp psoriasis. One hundred twenty-seven patients with a clinical diagnosis of scalp psoriasis and a baseline scalp Physician Global Assessment ≥3 were enrolled; 65 patients were treated with anti-IL23 and anti-IL62 with anti-IL17 or anti-IL17RA. Statistical analysis trough χ² test was performed in order to evaluate the percentage of response among the two groups of patients. Responders' percentage of patients under anti-IL23 was 41.5%, 75.4%, 88.1%, 87.5%, 93.7%, and 100% at Week 4, 16, 48, 96, and 144, respectively. In the group on anti-IL17 was 62.9%, 90.3%, 91.2%, 97.3%, 96.9%, and 95.2% at Week 4, 16, 48, 96, and 144, respectively. Both anti-IL17 and anti-IL23 appeared to be effective on scalp psoriasis; in particular patients treated with anti-IL17 drugs reached a faster significant reduction of the lesions; on the other hand, anti-IL23 monoclonal antibodies were slightly superior in maintaining the clinical improvement through the follow-up.本数据集包含与论文《抗IL-17与抗IL-23生物制剂治疗头皮银屑病：一项单中心回顾性对照研究》相关的原始数据。 摘要：头皮是银屑病的常见受累部位，对患者的生活质量可造成严重影响。该部位银屑病的临床管理通常颇具挑战，因此生物制剂被广泛用作难治性头皮银屑病的治疗选择。 本研究旨在回顾性对比抗白细胞介素23（Interleukin 23，IL-23）类药物（古塞库单抗、替拉珠单抗、瑞莎珠单抗）与抗IL-17或抗IL-17受体A（Interleukin 17 Receptor A，IL-17RA）生物制剂（司库奇尤单抗、依奇珠单抗、布罗达单抗）在头皮银屑病真实世界患者中的疗效。本研究共纳入127例经临床确诊为头皮银屑病且基线头皮医师整体评估（Physician Global Assessment，PGA）评分≥3的患者：其中65例接受抗IL-23治疗，62例接受抗IL-17或抗IL-17RA治疗。本研究采用χ²检验进行统计学分析，以评估两组患者的应答率。抗IL-23治疗组患者在第4、16、48、96、144周的应答率分别为41.5%、75.4%、88.1%、87.5%、93.7%和100%；抗IL-17治疗组患者在第4、16、48、96、144周的应答率分别为62.9%、90.3%、91.2%、97.3%、96.9%和95.2%。抗IL-17与抗IL-23类药物均对头皮银屑病显示出治疗效果：其中接受抗IL-17类药物治疗的患者皮损可实现更快的显著消退；而抗IL-23单克隆抗体在随访期间维持临床改善效果方面略胜一筹。